Contact: William Davis
University of North Carolina Health Care
Caption: Angiosarcoma cells treated with a monoclonal antibody targeting SFRP2 (right) show a significant reduction compared to an untreated control (left).
Credit: DeMore Lab, UNC School of Medicine
Usage Restrictions: None
Related news release: Novel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma